Outpace Bio
Seattle, US · Delaware corporation · 10 known investors
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
Founders & leadership
ML
Marc LajoieCo-founder & Chief Executive Officer
SB
Scott BoykenCo-founder & Chief Technology Officer
SR
Stanley RiddellCo-Founder and Scientific Advisor
AF
Aaron FosterExecutive Officer
CS
Charity ScriptureExecutive Officer
ES
Eric SollerExecutive Officer
JS
Jake SimsonDirector
VB
Vasudev BaileyDirector
BJ
Bahija JallalDirector
Investors · 10
Artis Ventures✓ verifiedSan Francisco · $50K – $25M
RA Capital✓ verifiedBostonvia Jake Simson · board
Abstract VenturesSan Francisco
Atinum Investment Co. Ltd.Seoul · $100K – $2M
Civilization Ventures Management, LlcTiburon · $1M – $10M
Modi VenturesHouston
Playground GlobalPalo Alto · $1M – $20M
Playground GlobalPalo Alto
AbstractreportedSan Francisco · $250K – $750K
Abstract VenturesreportedSan Francisco · $100K – $1M
Reported raises · per SEC filings
Form D private placements▶$56MraisedAug 2024 · 25 investors · BiotechnologyRule 506(b)
▶$56MraisedAug 2024 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jake SimsonDirector
- Aaron FosterExecutive Officer
- Bahija JallalDirector
- Vasudev BaileyDirector
- Charity ScriptureExecutive Officer
- Scott BoykenExecutive Officer, Director, Promoter
- Eric SollerExecutive Officer
- Marc LajoieExecutive Officer, Director, Promoter
- Offering amount
- $144.2M
- Amount sold
- $56M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.